iShares Genomics Immunology and Healthcare ETF
IDNA
67 hedge funds and large institutions have $46.7M invested in iShares Genomics Immunology and Healthcare ETF in 2022 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 15 increasing their positions, 17 reducing their positions, and 14 closing their positions.
2.64% less ownership
Funds ownership: 30.34% → 27.7% (-2.6%)
8% less funds holding
Funds holding: 73 → 67 (-6)
12% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 17
18% less capital invested
Capital invested by funds: $57.1M → $46.7M (-$10.4M)
43% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$1.76M |
| 2 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$1.74M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$1.15M |
| 4 |
Nomura Asset Management
Tokyo,
Japan
|
+$701K |
| 5 |
LRPA
L. Roy Papp & Associates
Phoenix,
Arizona
|
+$501K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$2.37M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.8M |
| 3 |
UCIG
Ulrich Consultants & Investment Group
Albuquerque,
New Mexico
|
-$1.35M |
| 4 |
Goldman Sachs
New York
|
-$1.18M |
| 5 |
Baird Financial Group
Milwaukee,
Wisconsin
|
-$963K |
IDNA Hedge Fund Activity: Q3 2022 in Review
67 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in iShares Genomics Immunology and Healthcare ETF (IDNA) for Q3 2022, worth a combined $46.7M — down 18% from $57.1M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of IDNA and 8 opened new positions — a net loss of 6 holders — while 17 trimmed existing stakes and 15 added.
The largest buyer was Morgan Stanley, adding an estimated $1.76M. The largest seller was Jane Street, cutting an estimated $2.37M.
- 67 institutional investors held iShares Genomics Immunology and Healthcare ETF (IDNA) as of Q3 2022, down from 73 in Q2 2022.
- Funds reported $46.7M of iShares Genomics Immunology and Healthcare ETF stock for Q3 2022, down 18% quarter-over-quarter.
- 8 funds opened new iShares Genomics Immunology and Healthcare ETF positions in Q3 2022 and 14 closed out, a net change of -6 holders.
- The largest iShares Genomics Immunology and Healthcare ETF buyer in Q3 2022 was Morgan Stanley, an estimated $1.76M added.
- The largest iShares Genomics Immunology and Healthcare ETF seller in Q3 2022 was Jane Street, an estimated $2.37M sold.
Based on aggregated 13F filings for Q3 2022.